Feasibility Study of Uterine Transplantation From Living Donors in Terms of Efficacy and Safety in Patients With Mayer-Rokitansky-Küster-Hauser Syndrome (MRKH)

In France, one in 4500 women is affected by the MayerRokitantskyKüsterHauser (MRKH) syndrome which is characterized by the absence of uterus at birth. Currently, the only solutions for these patients are: * Gestational surrogacy, prohibited in France * Adoption * Resignation Uterine transplantation could become a good alternative. This study is conducted in 10 patients with MRKH type I syndrome, who will be transplanted from a living donor uterus

NCT Number	NCT03689842
Lead Sponsor	Hopital Foch
Conditions	Mayer Rokitansky Kuster Hauser Syndrome
Enrollment	20 participants
Start Date	2017-12-14
Primary Completion	2027-12-14 (estimated)
Study Completion	2034-12-14 (estimated)
Updated on ClinicalTrials.gov	2025-03-07